Hong Kong Packaging Stock News

SEHK:710
SEHK:710Electronic

BOE Varitronix (SEHK:710) Margin Compression Tests Bullish Growth Narratives

BOE Varitronix (SEHK:710) has put fresh numbers on the table for FY 2025, with first half revenue of HK$6.7b, basic EPS of HK$0.23 and net income of HK$180.5m setting the tone for how investors will read the latest update. The company has seen revenue move from HK$6.2b in 1H 2024 to HK$7.3b in 2H 2024 and HK$6.7b in 1H 2025, while basic EPS tracked at HK$0.22 in 1H 2024, HK$0.28 in 2H 2024 and HK$0.23 in 1H 2025. This puts the spotlight squarely on how margins are holding up through the...
SEHK:6181
SEHK:6181Luxury

Laopu Gold (SEHK:6181) EPS Surge To C¥13.38 Tests Bullish Growth Narratives

Laopu Gold (SEHK:6181) has released its FY 2025 numbers with first half revenue of C¥12.4b and basic EPS of C¥13.38, set against trailing twelve month revenue of C¥27.3b and EPS of C¥28.35 that reflect earnings growth of 230.5% over the past year and an average of 66.3% per year over five years. Over recent periods the company has seen revenue move from C¥3.5b in 1H 2024 to C¥5.0b in 2H 2024 and then to C¥12.4b in 1H 2025, while basic EPS has shifted from C¥4.11 to C¥5.27 and then to C¥13.38,...
SEHK:81
SEHK:81Real Estate

China Overseas Grand Oceans Group (SEHK:81) Tight 0.8% Margin Reinforces Bearish Profitability Narratives

China Overseas Grand Oceans Group (SEHK:81) has put fresh numbers on the table for FY 2025, with first half revenue at C¥14.5b and basic EPS of C¥0.08. The trailing 12 month view shows revenue of C¥36.9b and EPS of C¥0.09 as the broader backdrop. Over the past three reported halves, revenue has moved from C¥21.9b in 1H 2024 to C¥24.0b in 2H 2024 and then to C¥14.5b in 1H 2025, with basic EPS shifting from C¥0.25 to C¥0.02 and then C¥0.08. This sets up a mixed picture that investors will weigh...
SEHK:1610
SEHK:1610Food

Trailing Loss Of C¥745.9m At COFCO Joycome Foods (SEHK:1610) Tests Bullish Recovery Narratives

COFCO Joycome Foods (SEHK:1610) has put fresh numbers on the table for FY 2025, with first half revenue of C¥8.96b and basic EPS of C¥0.07, while trailing 12 month figures show revenue of C¥18.58b paired with a basic EPS loss of C¥0.16. Over recent reporting periods, the company has seen revenue move from C¥7.48b and EPS of C¥0.07 in the first half of 2024 to C¥11.76b and EPS of C¥0.06 in the second half of 2024, before landing at the current mid year run rate. This sets up a picture where...
SEHK:1983
SEHK:1983Banks

Luzhou Bank (SEHK:1983) Margin Compression Challenges Bullish Earnings Growth Narrative

Luzhou Bank (SEHK:1983) has put fresh numbers on the table for FY 2025, with fourth quarter revenue of C¥952.5 million and net income of C¥273.6 million, underpinned by trailing twelve month revenue of C¥4.2 billion and net income of C¥1.5 billion on EPS of C¥0.53. Over recent periods the bank has seen quarterly revenue move between C¥445.2 million and C¥1.2 billion and EPS range from C¥0.04 to C¥0.17. This gives a clearer sense of how the top and bottom lines have tracked into the latest...
SEHK:2155
SEHK:2155Machinery

Morimatsu International Holdings (SEHK:2155) Margin Compression Challenges Bullish Growth Narratives

Morimatsu International Holdings (SEHK:2155) has opened FY 2025 with first half revenue of C¥2.7b and basic EPS of C¥0.28, against a backdrop of trailing 12 month EPS of C¥0.49. Over recent periods, the company has seen revenue move from C¥3.5b in 1H 2024 to C¥3.5b in 2H 2024 and C¥2.7b in 1H 2025, while basic EPS shifted from C¥0.32 to C¥0.30 and then C¥0.28. This puts the spotlight firmly on how margins are holding up as the growth story is weighed against recent profitability pressure. See...
SEHK:1061
SEHK:1061Biotechs

Essex Bio Technology SEHK 1061 Margin Drift Tests Bullish Undervaluation Narrative

Essex Bio-Technology (SEHK:1061) has opened FY 2025 with first half revenue of HK$876.5 million and basic EPS of HK$0.29, setting the tone for how investors will read the latest set of numbers. The company has seen revenue move from HK$828.5 million in 1H 2024 to HK$858.2 million in 2H 2024 and then HK$876.5 million in 1H 2025, while basic EPS shifted from HK$0.28 to HK$0.26 and then HK$0.29 over the same periods. This gives a clear view of how the top and bottom lines are tracking into the...
SEHK:2268
SEHK:2268Life Sciences

WuXi XDC Cayman (SEHK:2268) Margin Slip Tests Bullish Growth Narrative After FY 2025 Earnings

WuXi XDC Cayman (SEHK:2268) has posted FY 2025 results that put the focus squarely on scale, with second half revenue of C¥3.2b and basic EPS of C¥0.60, underpinned by trailing twelve month revenue of C¥5.9b and EPS of C¥1.22. The company has seen revenue move from C¥2.4b in the second half of 2024 to C¥3.2b in the second half of 2025, with basic EPS over that period shifting from C¥0.48 to C¥0.60 as investors weigh a trailing net margin of 24.9% against a slightly lower level a year ago. See...
SEHK:386
SEHK:386Oil and Gas

Is It Time To Reassess Sinopec (SEHK:386) After The Recent Share Price Pullback?

Wondering whether China Petroleum & Chemical at HK$4.53 still offers value, or if the easy gains are behind it? This article walks through what the current price really reflects. The stock has seen a 5.0% decline over the last 7 days and a 16.3% decline over the last 30 days, yet it shows returns of 15.5% over 1 year, 23.5% over 3 years and 67.3% over 5 years. Recent market conversations around China Petroleum & Chemical have focused on how its share price performance lines up with broader...
SEHK:6990
SEHK:6990Biotechs

Is It Time To Reassess Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) After Recent Share Price Weakness?

Wondering whether Sichuan Kelun-Biotech Biopharmaceutical is still priced attractively, or if the easy value has already been taken? This breakdown focuses squarely on what you are paying versus what you are getting. The share price recently closed at HK$397.60, after a 4.4% decline over the last week and a 4.6% decline over the past month, while the 1 year return sits at 52.6%. Recent news coverage has focused on Sichuan Kelun-Biotech Biopharmaceutical in the context of investor interest in...
SEHK:3931
SEHK:3931Auto Components

A Look At CALB Group (SEHK:3931) Valuation After FTSE All World Index Inclusion

CALB Group’s FTSE All-World inclusion puts index demand in focus CALB Group (SEHK:3931) was recently added to the FTSE All-World Index, a move that can attract attention from index tracking funds and ETFs that adjust their holdings to mirror index changes. See our latest analysis for CALB Group. The index inclusion follows firm share price momentum, with a 1-day share price return of 5.46% and a 1-year total shareholder return of 57.20%, suggesting that buying interest has been building...
SEHK:2858
SEHK:2858Consumer Finance

A Look At Yixin Group (SEHK:2858) Valuation After Recent Share Price Volatility

Event context and recent share performance Yixin Group (SEHK:2858) has come back into focus after a sharp single day move, with the share price down about 3.5%. This extends a one-month slide of roughly 15.6% and a similar decline over the past three months. See our latest analysis for Yixin Group. The recent 1-day share price return of negative 3.5% adds to a softer trend over the past month and quarter, although the 1-year total shareholder return of 35.9% and 3-year total shareholder...
SEHK:257
SEHK:257Commercial Services

Assessing China Everbright Environment Group’s Valuation After Full Year Earnings And Project Expansion Updates

Why China Everbright Environment Group’s latest earnings matter for investors China Everbright Environment Group (SEHK:257) has drawn fresh attention after reporting full year 2025 earnings, with net income of HK$3,925.16 million and basic EPS of HK$0.639, alongside lower sales of HK$27,520.51 million. See our latest analysis for China Everbright Environment Group. The earnings update and focus on project expansion come after a period of steady share price gains, with a 1 month share price...
SEHK:700
SEHK:700Interactive Media and Services

Is Tencent (SEHK:700) Turning Its AI Push Into a Durable WeChat Monetization Strategy?

Tencent Holdings Limited recently reported fourth-quarter 2025 revenue of CNY 194,371 million and net income of CNY 58,260 million, alongside a proposed annual dividend of HKD 5.30 per share payable on June 1, 2026. At the same time, Tencent’s expanded push into AI agents, including integrating ClawBot into WeChat, has highlighted both its product innovation and investor concerns about how these AI initiatives will translate into clear monetization. Now we’ll examine how Tencent’s...
SEHK:175
SEHK:175Auto

Assessing Geely Automobile Holdings (SEHK:175) Valuation After Its 2025 Results And Higher Dividend

What Geely’s 2025 results mean for shareholders Geely Automobile Holdings (SEHK:175) has put fresh numbers on the table, reporting its full year 2025 results and highlighting higher sales, steady earnings, and a higher ordinary final cash dividend that could matter for income focused investors. See our latest analysis for Geely Automobile Holdings. These results and the higher dividend have arrived alongside a clear shift in sentiment, with a 19.05% 1 month share price return and a 15.42% 1...
SEHK:1757
SEHK:1757Construction

Assessing Global Chinese Business Club (SEHK:1757) Valuation After China E Commerce Platform Announcement

China e-commerce launch puts Global Chinese Business Club in focus Global Chinese Business Club (SEHK:1757) has drawn fresh attention after announcing plans for a new China business: a comprehensive e-commerce platform linking suppliers and consumers with O2O services and integrated B2B and B2C functions. See our latest analysis for Global Chinese Business Club. The recent China e-commerce announcement comes after a strong run in the shares, with a 30 day share price return of 51.19% and very...
SEHK:975
SEHK:975Metals and Mining

Assessing Mongolian Mining (SEHK:975) Valuation After Weaker 2025 Earnings And Margin Compression

Full year 2025 earnings reset expectations for Mongolian Mining Mongolian Mining (SEHK:975) has come under the spotlight after releasing full year 2025 results, with sales of US$823.4 million and net income of US$6.1 million, both below the prior year’s levels. See our latest analysis for Mongolian Mining. The weak 2025 earnings release appears to have added pressure to a share price that already had a 30 day share price return of a 17.41% decline, although longer term total shareholder...
SEHK:2259
SEHK:2259Metals and Mining

Zijin Gold International (SEHK:2259) Margin Expansion Reinforces Bullish Community Narratives

Zijin Gold International (SEHK:2259) has reported its FY 2025 first half results with revenue of US$1.997b and basic EPS of US$0.23, against a backdrop of trailing 12 month EPS of US$0.56 supported by revenue of US$3.584b. Over recent half year periods the company has seen revenue move from US$1.403b and EPS of US$0.39 in 1H 2024 to US$1.587b and EPS of US$0.49 in 2H 2024, then to the latest 1H 2025 levels. This sequence gives investors a clearer view of the current earnings run rate. With...
SEHK:1299
SEHK:1299Insurance

A Look At AIA Group’s Valuation As Buyback Earnings And Governance Updates Land Together

Earnings, Buyback, and Governance Changes Shape AIA Group’s Latest Update AIA Group (SEHK:1299) has paired a new share repurchase program of up to US$1,743 million with its latest full year earnings release, while also updating investors on board committee changes and oversight structures. For the year ended December 31, 2025, AIA Group reported net income of US$6,234 million, compared with US$6,836 million a year earlier. Basic earnings per share from continuing operations came in at...
SEHK:3933
SEHK:3933Pharmaceuticals

A Look At United Laboratories (SEHK:3933) Valuation After 2025 Earnings Guidance And Insulin Degludec Approval

Why United Laboratories’ latest guidance and insulin approval matter for investors United Laboratories International Holdings (SEHK:3933) has issued 2025 earnings guidance pointing to lower group profit, alongside a fresh China approval for its Insulin Degludec Injection, a combination that could reshape how investors think about its earnings mix. See our latest analysis for United Laboratories International Holdings. The share price has eased to HK$10.48, with a 1-day share price return of...
SEHK:1286
SEHK:1286Machinery

A Look At Impro Precision Industries (SEHK:1286) Valuation After Strong Results And Second Interim Dividend

Impro Precision Industries (SEHK:1286) has paired its latest full year earnings release with a second interim dividend of HK$0.08 per share, giving investors fresh numbers and a cash return to assess together. See our latest analysis for Impro Precision Industries. The latest HK$7.98 share price comes after a strong run, with a 90 day share price return of 67.65% and a 1 year total shareholder return of 180.17%, suggesting momentum has been building around the recent earnings and dividend...